Vanguard Global Advisers
ALGS icon

Vanguard Global Advisers’s Aligos Therapeutics ALGS Stock Holding History

Vanguard Global Advisers’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-936
Closed -$6.95K – 3644
2026
Q1 		$6.95K Buy
+936
New +$7.1K ﹤0.01% 3524

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's ALGS Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Aligos Therapeutics (ALGS) in Q2 2026, closing a stake of 936 shares — an estimated $6.95K sold.

Vanguard Global Advisers first reported a position in ALGS in Q1 2026 and held it in 1 quarter. The position peaked at $6.95K in Q1 2026. 29 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Aligos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 936 Aligos Therapeutics shares in Q2 2026, an estimated $6.95K.
  • Vanguard Global Advisers first reported a position in Aligos Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Aligos Therapeutics position peaked at $6.95K in Q1 2026.
  • 29 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.